In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

The altered expression of autophagy-related genes participates in heart failure: NRBP2 and CALCOCO2 decrease left ventricular function in human dilated cardiomyopathy

Session Poster Session 3

Speaker Luis Martinez Dolz

Congress : Heart Failure 2019

  • Topic : basic science
  • Sub-topic : Basic Science - Cardiac Diseases: Cardiomyopathies
  • Session type : Poster Session
  • FP Number : P1881

Authors : E Rosello-Lleti (Valencia,ES), C Gil-Cayuela (Valencia,ES), A Lopez (Valencia,ES), L Martinez-Dolz (Valencia,ES), JR Gonzalez-Juanatey (Santiago de Compostela,ES), F Lago (Santiago de Compostela,ES), M Portoles (Valencia,ES)

E Rosello-Lleti1 , C Gil-Cayuela1 , A Lopez2 , L Martinez-Dolz3 , JR Gonzalez-Juanatey4 , F Lago4 , M Portoles1 , 1Health Research Institute of the Hospital La Fe (IIS La Fe) & CIBERCV (Institute Carlos III, Madrid), Myocardial Dysfunction and Heart Transplant - Valencia - Spain , 2Health Research Institute of the Hospital La Fe (IIS La Fe), Myocardial Dysfunction and Heart Transplant - Valencia - Spain , 3University Hospital La Fe, Heart Failure and Transplantation Unit - Valencia - Spain , 4Instituto de Investigación Sanitaria de Santiago, Cellular and Molecular Cardiology Research Unit - Santiago de Compostela - Spain ,


Background: Dilated cardiomyopathy (DCM) frequently results in heart failure, a syndrome with an increasingly high prevalence and mortality rate. Recently, we reported changes in expression and structural alterations in Golgi apparatus of patients with DCM. This organelle has been described as a potential source for autophagosomes development, an essential stage of the autophagy mechanism.

Purpose: This study aimed to analyze changes in the expression of autophagy- and phagocytosis-related genes in patients with DCM, especially in relation to left ventricular (LV) dysfunction. Furthermore, we investigated if the gene expression changes were translated into ultrastructural alterations.

Methods: Twenty-three human left ventricle tissue samples were obtained from DCM (n = 13) patients undergoing heart transplantation and control (CNT; n = 10) donors. Diagnosis of DCM was based on clinical history, Doppler echocardiography, and coronary angiography data. Total mRNA levels of heart samples were analyzed by RNA sequencing. Furthermore, transmission electron microscopy of the diseased tissue was carried out by a JEOL TEM system.

Results: The altered expression (P < 0.05) of 13 autophagy- and 3 phagocytosis-related genes was observed. The expression changes of the autophagy-related genes NRBP2 and CALCOCO2 were associated with cardiac dysfunction and remodeling (P < 0.05). The affected patients had a higher activity of these degradation processes, as evidenced by the greater number of autophagic structures in the DCM tissue (P < 0.001). Differences in the ultrastructural distribution were also found between the DCM and CNT tissues.

Conclusions: These results show that in patients with DCM, the altered expression of NRBP2 and CALCOCO2 is related to LV dysfunction and remodeling. Clarification of the molecular mechanisms of cardiac autophagy would help in the future development of therapies to improve LV performance.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are